AdultPediatricDosage Forms & Strengths capsule: Schedule V 25mg 50mg 75mg 100mg 150mg 200mg 225mg 300mg oral solution: Schedule V 20mg/mL tablet, extended-release: Schedule V 82.5 mg 165 mg 330 mg Diabetic Peripheral Neuropathic Pain Regular-release capsules Initial: 50 mg PO q8hr Maintenance: May increase to 100 mg PO q8hr within 1 week, as needed; not to exceed 300 mg/day Extended-release tablets Initial: 165 mg PO qDay Maintenance: May increase to 330 mg PO qDay within 1 week based on response and tolerability; not to exceed 330 mg PO qDay See also Administration Postherpetic Neuralgia Regular-release capsules Initial: 150-300 mg/day PO divided q8-12hr Maintenance: May increase to 300 mg/day divided q8-12hr after 1 week, as needed Extended-release tablets Initial: 165 mg PO qDay Maintenance: May increase to 330 mg PO qDay within 1 week based on response and tolerability; not to exceed 330 mg PO qDay Patients experiencing insufficient pain relief following 2-4 weeks of treatment with 330 mg PO qDay and tolerate the ER tablets, may be treated with up to 660 mg PO qDay Fibromyalgia Regular-release capsules and oral solution only Initial: 75 mg PO q12hr (150 mg/day) Maintenance: May increase to 150mg q12hr after 1 week as needed; recommended dose is 300-400 mg/day Owing to dose-dependent adverse reactions, doses >450 mg/day are not recommended Partial Onset Seizures Regular-release capsules and oral solution only Indicated as adjunctive therapy for treatment of partial onset seizures Initial: 150 mg/day PO divided q8-12hr Maintenance: Based on clinical response and tolerability, may increase dose in weekly increments, not to exceed 600 mg/day Efficacy of adjunctive pregabalin in patients taking gabapentin has not been evaluated in controlled trials; consequently, no dosing recommendations can be made when pregabalin is used with gabapentin Neuropathic Pain With Spinal Cord Injury Regular-release capsules and oral solution only Initial: 75 mg PO q12hr (150 mg/day); may increase within 1 week to 300 mg/day PO divided q12hr If there is insufficient pain relief after 2-3 weeks and 300 mg/day dose is tolerated, may increase dose again up to 600 mg/day PO divided q12hr Dosage Modifications Renal impairment (capsules/oral solution) CrCl 30-60 mL/min Decrease dose by 50% divided BID/TID CrCl 15-30 mL/min If 150 mg/day in normal renal function: Decrease dose to 25-50 mg/day; administer qDay or BID If 300 mg/day in normal renal function: Decrease dose to 75 mg/day; administer qDay or BID If 450 mg/day in normal renal function: Decrease dose to 100-150 mg/day; administer qDay or BID If 600 mg/day in normal renal function: Decrease dose to 150 mg/day; administer qDay or BID CrCl <15 mL/min If 150 mg/day in normal renal function: Decrease dose to 25 mg/day; qDay If 300 mg/day in normal renal function: Decrease dose to 25-50 mg/day; qDay If 450 mg/day in normal renal function: Decrease dose to 50-75 mg/day; qDay If 600 mg/day in normal renal function: Decrease dose to 75 mg/day; qDay Supplemental dosage following hemodialysis 25 mg qDay regimen: Take 1 supplemental dose of 25 mg or 50 mg 25-50 mg qDay regimen: Take 1 supplemental dose of 50 mg or 75 mg 50-75 mg qDay regimen: Take 1 supplemental dose of 75 mg or 100 mg 75 mg qDay regimen: Take 1 supplemental dose of 100 mg or 150 mg Renal impairment (ER tablets) CrCl 30-60 mL/min If 165 mg/day in normal renal function: Decrease dose to 82.5 mg/day If 330 mg/day in normal renal function: Decrease dose to 165 mg/day If 495 mg/day in normal renal function: Decrease dose to 247.5 mg/day If 660 mg/day in normal renal function: Decrease dose to 330 mg/day CrCl <30 mL/min or hemodialysis Not recommended Patients should only receive capsules or oral solution Dosing Considerations Conversion from capsules or oral solution (Lyrica) to ER tablets (Lyrica CR) Lyrica total daily dose (TDD) 75 mg/day = Lyrica CR 82.5 mg/day Lyrica TDD 150 mg/day = Lyrica CR 165 mg/day Lyrica TDD 225 mg/day = Lyrica CR 247.5 mg/day Lyrica TDD 300 mg/day = Lyrica CR 330 mg/day (3 × 82.5 mg tablets) Lyrica TDD 450 mg/day = Lyrica CR 495 mg/day (3 × 165 mg tablets) Lyrica TDD 600 mg/day = Lyrica CR 660 mg/day (2 × 330 mg tablets) Dosage Forms & Strengths capsule: Schedule V 25mg 50mg 75mg 100mg 150mg 200mg 225mg 300mg oral solution: Schedule V 20mg/mL Partial Onset Seizures Regular-release capsules and oral solution only Indicated as adjunctive therapy for treatment of partial onset seizures in patients aged ≥1 month <1 month: Safety and efficacy not established ≥1 month to <17 years 11 kg to <30 kg Initial: 3.5 mg/kg/day PO divided q8hr (for 1 month to 4 years) or q8-12hr (for ≥4 years) Maintenance: Based on clinical response and tolerability, may increase dose in weekly increments, not to exceed 14 mg/kg/day ≥30 kg Initial: 2.5 mg/kg/day PO divided q8-12hr Maintenance: Based on clinical response and tolerability, may increase dose in weekly increments up to 10 mg/kg/day (not to exceed 600 mg/day) ≥17 years Initial: 150 mg/day PO divided q8-12hr Maintenance: Based on clinical response and tolerability, may increase dose in weekly increments, not to exceed 600 mg/day Fibromyalgia Safety and efficacy not established A 15-week, placebo-controlled trial (n=107) was conducted in pediatric patients with fibromyalgia aged 12-17 yr with pregabalin (75-450 mg/day) The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity (derived from an 11-point numeric rating scale) showed numerically greater improvement for the pregabalin-treated patients compared to placebo-treated patients, but did not reach statistical significance Dosage Modifications Renal impairment: Use in children with compromised renal function has not been studiedInteraction CheckerEnter a drug name and pregabalinNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (20)benazeprilbenazepril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and pregabalin both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine subdermal implantbuprenorphine subdermal implant and pregabalin both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and pregabalin both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and pregabalin both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecaptoprilcaptopril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.enalaprilenalapril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.everolimuseverolimus, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.fosinoprilfosinopril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.imidaprilimidapril, pregabalin. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive risk of developing angioedema of face, mouth, and neck, including respiratory compromise.lisinoprillisinopril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.metoclopramide intranasalpregabalin, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.moexiprilmoexipril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.olopatadine intranasalpregabalin and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. perindoprilperindopril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.quinaprilquinapril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.ramiprilramipril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.sirolimussirolimus, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.temsirolimustemsirolimus, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.trandolapriltrandolapril, pregabalin. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration results in additive risk of developing angioedema of face, mouth, and neck. Angioedema may result in respiratory compromise.Monitor Closely (133)acrivastineacrivastine and pregabalin both increase sedation. Use Caution/Monitor.alprazolampregabalin, alprazolam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.amisulprideamisulpride and pregabalin both increase sedation. Use Caution/Monitor.amitriptylinepregabalin, amitriptyline. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.amobarbitalpregabalin, amobarbital. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.amoxapinepregabalin, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.asenapineasenapine and pregabalin both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and pregabalin both increase sedation. Use Caution/Monitor.avapritinibavapritinib and pregabalin both increase sedation. Use Caution/Monitor.belladonna and opiumpregabalin, belladonna and opium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.benzhydrocodone/acetaminophenpregabalin, benzhydrocodone/acetaminophen. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.brexanolonebrexanolone, pregabalin. Either increases toxicity of the other by sedation. Use Caution/Monitor.pregabalin, brexanolone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.brexpiprazolepregabalin, brexpiprazole. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.brexpiprazole and pregabalin both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and pregabalin both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and pregabalin both increase sedation. Use Caution/Monitor.brompheniraminepregabalin, brompheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.buprenorphinepregabalin, buprenorphine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest